Latest / Glaucoma, Vision & Longevity: Supplements & Science / Can Glaucoma Damage Be Reversed? First Human Epigenetic Reprogramming Trial Targets the Optic Nerve

Transcript

Can Glaucoma Damage Be Reversed? First Human Epigenetic Reprogramming Trial Targets the Optic Nerve · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Can glaucoma damage be reversed?
• 0:02
  SPEAKER_00: First human epigenetic reprogramming trial targets the optic nerve.
• 0:07
  SPEAKER_00: Updated August 11, 2026.
• 0:10
  SPEAKER_00: Bottom line: ER-100 is the first human clinical trial of a partial epigenetic reprogramming therapy, but it is not yet evidence that glaucoma damage can be reversed in people.
• 0:20
  SPEAKER_00: Life Biosciences is testing ER-100 in a small, first-in-human phase one study involving adults with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.
• 0:31
  SPEAKER_00: The treatment delivers genetic instructions for three transcription factors, OT4, SOX-2, and KLF-4, collectively called OSK, to retinal ganglion cells using an adenoassociated virus type 2 vector.
• 0:44
  SPEAKER_00: Oral doxycycline is then used for eight weeks to activate the therapeutic genes.
• 0:49
  SPEAKER_00: Clinical trials.gov study record.
• 0:52
  SPEAKER_00: The scientific idea is fundamentally different from conventional glaucoma treatment.
• 0:57
  SPEAKER_00: Instead of lowering intraocular pressure, ER100 is intended to make damaged but living retinal ganglion cells behave more like younger, healthier cells.
• 1:06
  SPEAKER_00: The preclinical evidence is unusually ambitious.
• 1:09
  SPEAKER_00: Studies in mice reported retinal ganglion cell survival, optic nerve axon growth, improved electrical retinal responses, and improved visual behavior.
• 1:19
  SPEAKER_00: Company-presented nonhuman primate data reported recovery of pattern electroretinogram responses and improved optic nerve axon survival after an experimental optic nerve stroke.
• 1:31
  SPEAKER_00: However, the primate findings have been publicly described mainly through company disclosures and a 2023 Association for Research in Vision and Ophthalmology presentation rather than a detailed, independent, peer-reviewed clinical F-Efficacy publication, Nature Study.
• 1:48
  SPEAKER_00: Life Biosciences Primate Disclosure.
• 1:51
  SPEAKER_00: As of August 11, 2026, no human vision benefit, epigenetic reset, retinal ganglion cell regeneration, or long-term safety result has been publicly reported.
• 2:03
  SPEAKER_00: Life Biosciences has confirmed that the first participant was dosed, but the trial remains an early safety study with no results posted on clinicaltrials.gov.
• 2:12
  SPEAKER_00: First dose announcement Clinicaltrials.gov record.
• 2:16
  SPEAKER_00: The fairest conclusion is, glaucoma has not yet entered the era of proven optic nerve restoration.
• 2:22
  SPEAKER_00: It has entered the era of the first credible human experiment testing whether optic nerve cells can be rejuvenated rather than merely protected.
• 2:33
  SPEAKER_00: Why current glaucoma treatments do not reverse damage?
• 2:36
  SPEAKER_00: Glaucoma damages retinal ganglion cells, the nerve cells that collect visual information from the retina.
• 2:42
  SPEAKER_00: Their long axons form the optic nerve and carry signals to the brain.
• 2:46
  SPEAKER_00: Once retinal ganglion cells and their axons are permanently lost, current treatments cannot replace them.
• 2:52
  SPEAKER_00: Standard treatments, including eye drops, laser treatment, and glaucoma surgery, primarily reduce intraocular pressure.
• 3:00
  SPEAKER_00: Lowering pressure can slow or prevent additional optic nerve damage, but it does not normally restore lost visual field.
• 3:07
  SPEAKER_00: National Eye Institute, American Academy of Ophthalmology Patient Information.
• 3:12
  SPEAKER_00: This is why glaucoma care is generally described as preservation rather than restoration.
• 3:18
  SPEAKER_00: Lowering pressure remains the only proven treatment strategy for controlling ordinary open-angle glaucoma, although disease progression can sometimes continue even when pressure is considered acceptable.
• 3:31
  SPEAKER_00: National Institute for Health and Care Excellence.
• 3:34
  SPEAKER_00: The difficulty is not only that retinal ganglion cells die, their axons must also travel through the optic nerve and connect with appropriate visual centers in the brain.
• 3:45
  SPEAKER_00: The National Eye Institute has emphasized that the failure of adult human retinal ganglion cells to regenerate and reconnect explains much of the irreversibility of optic nerve-related vision loss.
• 3:57
  SPEAKER_00: National Eye Institute Optic Nerve Regeneration Report.
• 4:01
  SPEAKER_00: ER100 is designed to intervene at a different level.
• 4:05
  SPEAKER_00: Conventional treatment, reduce the mechanical stress caused by intraocular pressure.
• 4:10
  SPEAKER_00: ER100, alter gene regulation inside retinal ganglion cells.
• 4:15
  SPEAKER_00: Potential goal preserve stressed cells, restore the function of injured cells, and possibly reactivate some regenerative capacity.
• 4:23
  SPEAKER_00: ER100 is therefore not a replacement for pressure control.
• 4:27
  SPEAKER_00: Even if it works, a person with glaucoma would still be expected to need standard treatment to reduce the original disease stress.
• 4:34
  SPEAKER_00: What ER100 is?
• 4:36
  SPEAKER_00: ER100 is described by life biosciences as AAV2OSK, an adeno-associated virus type 2 vector carrying genetic instructions for OCT4, SOX2, and KLF4.
• 4:49
  SPEAKER_00: The vector is administered by an intravitreal injection, meaning an injection into the gel-like vitreous cavity inside the eye.
• 4:57
  SPEAKER_00: The vector is intended to deliver the OSK instructions mainly to retinal ganglion cells.
• 5:03
  SPEAKER_00: It is not designed to edit the patient's existing DNA sequence in the way a genome editing system would.
• 5:09
  SPEAKER_00: However, that does not mean it carries no genetic or biological risk.
• 5:13
  SPEAKER_00: The vector can persist in cells, transgene expression may vary, and rare vector genome integration is a general consideration in gene therapy.
• 5:22
  SPEAKER_00: The treatment includes a separate control mechanism.
• 5:26
  SPEAKER_00: According to the clinical trials.gov record, the patient receives a single dose of ER100.
• 5:31
  SPEAKER_00: The viral vector remains in the eye.
• 5:34
  SPEAKER_00: The patient takes oral doxycycline for 56 days.
• 5:37
  SPEAKER_00: Doxycycline activates OSK expression through an inducible genetic switch.
• 5:42
  SPEAKER_00: Doxycycline is stopped after eight weeks.
• 5:45
  SPEAKER_00: The exact numeric vector doses for the dose escalation groups have not been publicly listed in the main clinical trials.gov record.
• 5:53
  SPEAKER_00: The trial states that at least two dose levels will be assessed in the open angle glaucoma cohort.
• 6:00
  SPEAKER_00: What?
• 6:00
  SPEAKER_00: Epigenetic reprogramming means the epigenome consists of chemical and structural controls that influence which genes are turned on or off.
• 6:09
  SPEAKER_00: These controls include DNA methylation, chemical changes to histone proteins, and changes in how DNA is packaged.
• 6:17
  SPEAKER_00: Epigenetic reprogramming does not necessarily change the underlying DNA letters.
• 6:22
  SPEAKER_00: Instead, it attempts to alter the instructions that determine how the cell reads its existing genome.
• 6:28
  SPEAKER_00: The theory behind ER100 is that aging and injury gradually disturb the gene regulation program that keeps retinal ganglion cells functional.
• 6:36
  SPEAKER_00: According to this model, some of the damage may be a loss of youthful cellular information rather than irreversible destruction of every component of the cell.
• 6:46
  SPEAKER_00: OSK is intended to push the cell toward a younger gene expression state without converting it completely into a stem cell.
• 6:54
  SPEAKER_00: How OCT4, SOX2, and KLF4 are supposed to rejuvenate retinal ganglion cells.
• 7:00
  SPEAKER_00: The three factors are transcription factors.
• 7:02
  SPEAKER_00: They bind DNA and influence large networks of other genes.
• 7:06
  SPEAKER_00: OCT4.
• 7:28
  SPEAKER_00: Instead, OCT4 is intended to help reopen or reorganize portions of the gene regulatory landscape associated with cellular repair and youthfulness.
• 7:37
  SPEAKER_00: SOX-2.
• 7:38
  SPEAKER_00: SOX-2 is another key reprogramming factor.
• 7:41
  SPEAKER_00: It helps alter chromatin accessibility, the degree to which DNA can be reached by gene-regulating proteins.
• 7:47
  SPEAKER_00: In retinal ganglion cells, this may help reactivate genes involved in neuronal maintenance, axon growth, stress resistance, and synaptic function.
• 7:56
  SPEAKER_00: The exact human retinal ganglion cell targets of ER100 remain unproven.
• 8:00
  SPEAKER_00: KLF4.
• 8:01
  SPEAKER_00: KLF-4 is involved in cell identity, chromatin regulation, stress responses, and reprogramming.
• 8:07
  SPEAKER_00: It works together with OCT4 and SOX-2 to alter gene expression networks.
• 8:12
  SPEAKER_00: The intended result is not simply a lower epigenetic age on a laboratory test.
• 8:17
  SPEAKER_00: The therapeutic claim is that the cells should function better, maintaining axonal transport, resisting injury, and potentially regaining some ability to extend or repair axons.
• 8:28
  SPEAKER_00: The proposed sequence of events?
• 8:30
  SPEAKER_00: The proposed mechanism can be summarized as age or injury alters gene regulation in retinal ganglion cells.
• 8:37
  SPEAKER_00: These cells become less able to maintain axons and respond to stress.
• 8:41
  SPEAKER_00: OSK temporarily changes transcription and chromatin organization.
• 8:46
  SPEAKER_00: DNA methylation patterns and gene expression move toward a more youthful state.
• 8:50
  SPEAKER_00: The retinal ganglion cells become more resilient or regain some regenerative capacity.
• 8:56
  SPEAKER_00: Visual signaling improves if enough cells and axons remain connected.
• 9:00
  SPEAKER_00: The mouse work supports several steps in this chain, but the complete sequence has not been demonstrated in humans.
• 9:06
  SPEAKER_00: The original Nature study reported that OSK restored youthful DNA methylation patterns and gene expression profiles in mouse retinal ganglion cells, and that the effect required the DNA demethylation machinery involving TET1, TET2, and TDG.
• 9:23
  SPEAKER_00: This is stronger evidence than merely showing that a methylation clock changed, but it still does not prove that aging in human glaucoma is primarily caused by epigenetic information loss.
• 9:33
  SPEAKER_00: Why ER100 uses three factors rather than all four Yamanaka factors?
• 9:39
  SPEAKER_00: The original four-factor reprogramming combination is OCT4, SOX2, KLF4, CMIC.
• 9:46
  SPEAKER_00: The four-factor combination is commonly called OSKM.
• 9:49
  SPEAKER_00: ER100 omits CMIC for two main reasons.
• 9:53
  SPEAKER_00: CMIC is a powerful oncogene.
• 9:55
  SPEAKER_00: CMIC promotes cell growth, metabolism, proliferation, and broad transcriptional changes.
• 10:01
  SPEAKER_00: It is also involved in many human cancers.
• 10:03
  SPEAKER_00: Although CMIC can make complete cellular reprogramming more efficient, it is not essential for initiating reprogramming.
• 10:10
  SPEAKER_00: Omitting it is intended to reduce the risks of uncontrolled growth and tumor formation.
• 10:15
  SPEAKER_00: Review of partial reprogramming.
• 10:18
  SPEAKER_00: Full OSKM reprogramming can erase cell identity.
• 10:22
  SPEAKER_00: When adult cells are exposed to the complete reprogramming program for long enough, they can become induced pluripotent stem cells.
• 10:30
  SPEAKER_00: That process involves a profound loss of their original identity.
• 10:34
  SPEAKER_00: For a retinal ganglion cell, this would be dangerous.
• 10:37
  SPEAKER_00: A rejuvenated retinal ganglion cell still needs to remain a retinal ganglion cell with its correct electrical properties, connections, and visual role.
• 10:46
  SPEAKER_00: The strategy behind ER100 is therefore, use enough reprogramming pressure to restore youthful function, but not enough to erase the identity of the retinal ganglion cell.
• 10:56
  SPEAKER_00: Mouse studies reported that OSK improved function without increasing cell proliferation or causing an obvious loss of retinal ganglion cell identity.
• 11:06
  SPEAKER_00: However, this is a safety finding in mice, not proof that the same dosage window exists in humans.
• 11:13
  SPEAKER_00: Nature Study.
• 11:14
  SPEAKER_00: Removing CMYC reduces one major hazard.
• 11:17
  SPEAKER_00: It does not eliminate all risks associated with OC4, SOX2, KLF-4, viral delivery, or incomplete reprogramming.
• 11:25
  SPEAKER_00: What the preclinical studies actually showed, the phrase restored vision can mean very different things in animal experiments.
• 11:32
  SPEAKER_00: It may refer to a behavioral visual acuity test, an electrical retinal response, a thicker retinal nerve fiber layer, more surviving axons, or a laboratory epigenetic marker.
• 11:43
  SPEAKER_00: These are not interchangeable.
• 11:45
  SPEAKER_00: The evidence should therefore be separated by model and endpoint.
• 11:49
  SPEAKER_00: Preclinical evidence summary.
• 11:51
  SPEAKER_00: For the full table, please open this article on visual field test docoptic nerve injury.
• 11:57
  SPEAKER_00: In the 2020 Nature study, OSK was delivered to mouse retinal ganglion cells using an inducible adenoassociated virus system.
• 12:05
  SPEAKER_00: In young and older mice, OSK increased retinal ganglion cell survival after optic nerve crush and promoted axon regeneration, measured using an anatomical tracer.
• 12:16
  SPEAKER_00: Importantly, the study reported no increase in cell proliferation.
• 12:20
  SPEAKER_00: Nature View's Neuroscience Summary.
• 12:23
  SPEAKER_00: This is meaningful because adult mammalian retinal ganglion cells normally have very limited ability to regenerate their axons.
• 12:30
  SPEAKER_00: However, tracer-positive axon growth is not the same as demonstrating that the regenerated axons navigated correctly through the entire optic nerve, reached the correct brain targets, formed appropriate synapses, and restored useful vision.
• 12:45
  SPEAKER_00: Mouse glaucoma.
• 12:47
  SPEAKER_00: In a mouse model in which elevated eye pressure produced glaucoma-like injury, OSK treatment was administered after visual damage had already developed.
• 12:56
  SPEAKER_00: The treated animals showed improved visual performance compared with controls.
• 13:01
  SPEAKER_00: The National Institute on Aging described the early result as recovery of roughly half of the previously lost visual ability in the glaucoma mice.
• 13:12
  SPEAKER_00: The original study also reported that OSK restored youthful gene expression and DNA methylation patterns in retinal ganglion cells.
• 13:21
  SPEAKER_00: The functional findings are more important than the methylation findings because a change in a molecular biomarker alone would not establish vision restoration.
• 13:30
  SPEAKER_00: The main limitation is that this was an induced mouse model.
• 13:34
  SPEAKER_00: Mouse glaucoma is not identical to decades-long human open-angle glaucoma, which may involve pressure sensitivity, vascular factors, inflammation, mitochondrial stress, aging, and gradual loss of retinal ganglion cells.
• 13:47
  SPEAKER_00: Long-term mouse follow-up better.
• 13:49
  SPEAKER_00: A later study tracked treated mice for approximately one year.
• 13:53
  SPEAKER_00: In that work, two months of OSK treatment reportedly restored visual performance to healthy levels in the experimental glaucoma model.
• 14:02
  SPEAKER_00: The improvement remained close to healthy levels for many months while OSK expression continued.
• 14:08
  SPEAKER_00: After doxycycline was withdrawn, OSK transcription returned toward baseline within approximately four weeks.
• 14:16
  SPEAKER_00: The visual benefit persisted for a period and then gradually declined, although it remained better than the untreated baseline for some time.
• 14:23
  SPEAKER_00: Sustained vision recovery by OESC gene therapy.
• 14:27
  SPEAKER_00: This suggests that OSK may trigger a durable cellular state rather than acting only while the factors are being expressed.
• 14:34
  SPEAKER_00: It also raises an important clinical question.
• 14:37
  SPEAKER_00: Would a human patient need repeated activation, repeat injections, or additional treatment if the benefit fades?
• 14:44
  SPEAKER_00: The study and later reviews reported no obvious tumor formation or major toxicity during the observed mouse period.
• 14:51
  SPEAKER_00: That is reassuring, but animal studies with limited numbers cannot exclude rare cancers, delayed changes in cell identity, or species-specific toxicity.
• 15:01
  SPEAKER_00: Independent glaucoma review.
• 15:03
  SPEAKER_00: Aged mice without induced glaucoma OSK also improved visual performance in older mice without experimentally raising eye pressure.
• 15:11
  SPEAKER_00: Their retinal ganglion cells showed more youthful molecular patterns.
• 15:15
  SPEAKER_00: This supports the broader idea that aging itself may make retinal ganglion cells less resilient.
• 15:22
  SPEAKER_00: However, age-related visual decline in a mouse is not equivalent to the focal visual field loss caused by advanced human glaucoma.
• 15:30
  SPEAKER_00: Non-human primate optic neuropathy data.
• 15:33
  SPEAKER_00: Life biosciences reported results from a non-human primate model of non-arteritic anterior ischemic optic neuropathy, an experimental optic nerve stroke.
• 15:42
  SPEAKER_00: The injury was produced using laser damage.
• 15:45
  SPEAKER_00: Animals received an intravitreal injection of doxycycline-inducible OSK virus or vehicle one day later, and doxycycline was administered systemically.
• 15:55
  SPEAKER_00: Life Biosciences Association for Research in Vision and Ophthalmology Disclosure.
• 16:00
  SPEAKER_00: The company reported reduced pattern electroretinogram responses after injury, thinning or damage in retinal nerve fiber layer measurements, fewer healthy optic nerve axon bundles, significant recovery of pattern electroretinogram responses in OSK-treated eyes, and improved axon survival compared with controls.
• 16:19
  SPEAKER_00: This is important because primate retinal anatomy and visual pathways are more similar to humans than those of mice.
• 16:26
  SPEAKER_00: But several qualifications matter.
• 16:29
  SPEAKER_00: This was an ischemic optic neuropathy model, not a chronic glaucoma model.
• 16:33
  SPEAKER_00: Pattern electroretinogram is an electrical measure of retinal ganglion cell function, not the same as a patient reading an eye chart or recovering a measured visual field.
• 16:43
  SPEAKER_00: The publicly available information does not provide the full experimental detail normally needed to judge sample size, randomization, effect size, attrition, and independent replication.
• 16:56
  SPEAKER_00: The primate findings were presented publicly by the company at an ophthalmology meeting, they should not be treated as equivalent to a completed peer-reviewed human trial.
• 17:05
  SPEAKER_00: The study did not demonstrate replacement of dead retinal ganglion cells or definitive reconstruction of the entire visual pathway.
• 17:13
  SPEAKER_00: Life Biosciences also says its broader preclinical package showed OSCA expression in retinal ganglion cells, restoration of methylation patterns, improved pattern electroretinogram responses, improved axon architecture, and improved mouse optimotor responses.
• 17:31
  SPEAKER_00: Those claims are company summaries, and the public information is less detailed than the original mouse paper, Life Biosciences Preclinical.
• 17:39
  SPEAKER_00: The current Phase 1 Human Trial.
• 17:43
  SPEAKER_00: The trial is registered as NCT 729244 with the official title, A Phase 1 Single Dose Study to Evaluate the Safety and Tolerability of ER-100 in optic neuropathies.
• 17:55
  SPEAKER_00: It is sponsored by Life Biosciences and is being conducted at sites including Mass Eye and Ear, Columbia University, and other United States locations.
• 18:04
  SPEAKER_00: Clinicaltrials.gov.
• 18:06
  SPEAKER_00: Who can participate?
• 18:07
  SPEAKER_00: The study plans to enroll up to 18 adults, 12 participants with open angle glaucoma, 6 participants with non-arteritic anterior ischemic optic neuropathy.
• 18:18
  SPEAKER_00: Participants must generally be between 40 and 85 years old.
• 18:22
  SPEAKER_00: Open angle glaucoma cohort.
• 18:25
  SPEAKER_00: The glaucoma participants must have confirmed open angle glaucoma in the study eye, intraocular pressure below 30 mm of mercury, moderate to advanced visual field loss, a Humphrey visual field mean deviation between approximately minus 6 and minus 20 decibels, and best corrected visual acuity of at least approximately 2080.
• 18:47
  SPEAKER_00: They must not be expected to require glaucoma surgery in the treated eye within two months after dosing.
• 18:53
  SPEAKER_00: Clinical trials.gov eligibility criteria.
• 18:57
  SPEAKER_00: This is an important detail.
• 18:59
  SPEAKER_00: The trial is not primarily enrolling people with no remaining measurable vision or end stage destruction.
• 19:05
  SPEAKER_00: It is selecting eyes with substantial damage but enough remaining vision to undergo safety and functional testing.
• 19:12
  SPEAKER_00: Non-arteritic anterior ischemic optic neuropathy cohort.
• 19:16
  SPEAKER_00: The non-arteritic anterior ischemic optic neuropathy group must have experienced a sudden, painless loss of vision within 14 days before receiving ER-100.
• 19:26
  SPEAKER_00: The affected eye must show findings consistent with optic nerve injury, including optic disc swelling and a compatible visual field defect.
• 19:35
  SPEAKER_00: ClinicalTrials.gov.
• 19:37
  SPEAKER_00: This group is biologically different from chronic glaucoma.
• 19:40
  SPEAKER_00: After an acute optic nerve stroke, some cells may be injured but not yet dead.
• 19:45
  SPEAKER_00: That could make functional recovery easier to detect than in long-standing glaucoma.
• 19:50
  SPEAKER_00: How is the study organized?
• 19:52
  SPEAKER_00: The trial has two sequential stages open angle glaucoma dose escalation, non-arteritic anterior ischemic optic neuropathy dose expansion at a selected dose.
• 20:02
  SPEAKER_00: At each new glaucoma dose level, a single sentinel participant is treated first.
• 20:06
  SPEAKER_00: That person is monitored for 28 days before the Data Safety Monitoring Board reviews the results and permits treatment of additional participants at that dose.
• 20:16
  SPEAKER_00: ClinicalTrials.gov.
• 20:18
  SPEAKER_00: After the glaucoma dose is selected, up to three non-artteritic anterior ischemic optic neuropathy participants are initially treated.
• 20:26
  SPEAKER_00: The safety data are reviewed before enrollment expands to six participants.
• 20:31
  SPEAKER_00: The public registry does not list a randomized sham injection control group.
• 20:36
  SPEAKER_00: The principal comparisons are against each participant's baseline, which makes any apparent visual improvement difficult to interpret because visual field testing has learning effects, day-to-day variability, and regression toward the average.
• 20:50
  SPEAKER_00: How is ER100 administered?
• 20:53
  SPEAKER_00: The trial uses a single intravitreal injection, oral doxycycline for 56 days to activate OSK, and follow-up for up to five years.
• 21:03
  SPEAKER_00: The study includes approximately 15 clinic visits, with 10 visits in the first six months and annual visits through year 5, plus approximately two telephone visits.
• 21:13
  SPEAKER_00: Clinicaltrials.gov.
• 21:15
  SPEAKER_00: The public record describes dose escalation, but does not provide the numeric vector genome doses in its main summary.
• 21:23
  SPEAKER_00: It also specifies the eight-week doxycycline activation period without publicly stating the complete dosing details in the registry summary.
• 21:31
  SPEAKER_00: What will the trial measure?
• 21:33
  SPEAKER_00: The trial is primarily a safety and tolerability study, but it includes exploratory and secondary measures relevant to visual function.
• 21:40
  SPEAKER_00: Safety measures.
• 21:42
  SPEAKER_00: These include treatment emergent adverse events, dose limiting toxicities, eye examinations, intocular pressure, visual acuity, laboratory testing, including liver function tests, long term health monitoring, and slit lamp examination.
• 21:57
  SPEAKER_00: Visual and retinal measures.
• 21:59
  SPEAKER_00: The study includes.
• 22:00
  SPEAKER_00: Best corrected visual acuity using an early treatment diabetic retinopathy study letter chart.
• 22:06
  SPEAKER_00: Humphrey Visual Field Testing, 24-2 testing for open-angle glaucoma, a larger size 5 stimulus for non-arteritic anterior ischemic optic neuropathy.
• 22:16
  SPEAKER_00: Pattern Electroretinogram, measuring retinal ganglion cell-related electrical responses.
• 22:22
  SPEAKER_00: Optical coherence tomography measurements of the ganglion cell layer.
• 22:26
  SPEAKER_00: Quantitative contrast sensitivity, which measures the ability to detect subtle differences between light and dark.
• 22:33
  SPEAKER_00: Long-term monitoring of these measurements after doxycycline has stopped.
• 22:37
  SPEAKER_00: Clinical trials.gov outcome measures.
• 22:40
  SPEAKER_00: Immune and biodistribution measures.
• 22:42
  SPEAKER_00: The study will also examine antibodies against the adenoassociated virus vector, cellular immune responses against ER100 peptides, viral vector DNA in tears, saliva, blood, urine, nasal samples and feces, and vector DNA in aqueous humor in open angle glaucoma participants.
• 23:01
  SPEAKER_00: These tests are designed to assess whether the treatment remains localized, whether it is shed from the body, and whether the immune system recognizes the vector or its genetic payload.
• 23:13
  SPEAKER_00: What has actually happened in humans as of August 11, 2026?
• 23:17
  SPEAKER_00: Confirmed.
• 23:19
  SPEAKER_00: The following points are publicly documented.
• 23:21
  SPEAKER_00: Life Biosciences received authorization to proceed with first in-human testing in January 2026, according to the company.
• 23:30
  SPEAKER_00: The clinicaltrials.gov record lists the actual study start date as March 2nd, 2026.
• 23:37
  SPEAKER_00: Life Biosciences announced that the first participant was dosed on June 9, 2026.
• 23:43
  SPEAKER_00: The study is registered as a phase one trial with planned enrollment of up to 18 participants.
• 23:48
  SPEAKER_00: Clinicaltrials.gov lists the trial as recruiting and does not show posted study results.
• 23:54
  SPEAKER_00: The estimated primary completion date is May 2027.
• 23:58
  SPEAKER_00: The estimated overall study completion date is March 2032, reflecting the long-term gene therapy follow-up.
• 24:06
  SPEAKER_00: Left sciences, not confirmed.
• 24:09
  SPEAKER_00: There is no publicly confirmed human evidence that ER-100 has, restored visual field, improved visual acuity, increased ganglion cell layer thickness, improved pattern electroretinogram responses, reversed and epigenetic age measurement, regenerated optic nerve axons, or prevented glaucoma progression.
• 24:28
  SPEAKER_00: There is also no publicly posted human safety dataset establishing whether the treatment causes inflammation, immune reactions, dose limiting toxicity, or other adverse effects.
• 24:39
  SPEAKER_00: The company has announced that a participant was dosed.
• 24:42
  SPEAKER_00: That is not the same as announcing that the participant improved.
• 24:46
  SPEAKER_00: Company expectations versus observations.
• 24:49
  SPEAKER_00: For the full table, please open this article on Visual FieldTest.com.
• 24:53
  SPEAKER_00: Could ER100 restore an already lost visual field?
• 24:57
  SPEAKER_00: There are three different possibilities and they should not be confused.
• 25:01
  SPEAKER_00: Protecting surviving retinal ganglion cells.
• 25:04
  SPEAKER_00: This is the most realistic near-term possibility.
• 25:07
  SPEAKER_00: Some retinal ganglion cells may be stressed, electrically dysfunctional, or disconnected at the axon level without being completely dead.
• 25:16
  SPEAKER_00: If OSK improves their metabolism, axonal transport, or gene expression state, visual function could improve or decline more slowly.
• 25:24
  SPEAKER_00: That would be a meaningful advance, but it would be neuroprotection or functional rescue, not replacement of lost nerve cells.
• 25:32
  SPEAKER_00: Restoring function in injured axons.
• 25:35
  SPEAKER_00: The animal studies suggest that OSK can promote axon growth after optic nerve injury.
• 25:40
  SPEAKER_00: If some damaged axons remain structurally present but function poorly, reprogramming could potentially improve their function.
• 25:48
  SPEAKER_00: This is more ambitious than simple neuroprotection, but still different from rebuilding an entire optic nerve.
• 25:55
  SPEAKER_00: Regenerating and reconnecting lost axons.
• 25:58
  SPEAKER_00: This is the true optic nerve restoration scenario.
• 26:02
  SPEAKER_00: To restore a permanently lost visual field location, a therapy would generally need to preserve or replace an appropriate retinal ganglion cell, extend an axon through the optic nerve, guide it to the correct visual target in the brain, form effective synapses, and restore reliable visual processing.
• 26:20
  SPEAKER_00: The mouse optic nerve crush data demonstrate axon growth.
• 26:24
  SPEAKER_00: They do not establish that ER100 can perform all of these steps in a human with chronic glaucoma.
• 26:30
  SPEAKER_00: What is most likely in chronic glaucoma?
• 26:33
  SPEAKER_00: For a person with moderate glaucoma and many surviving retinal ganglion cells, a modest improvement in visual sensitivity or a slowing of further loss is biologically more plausible than recovery of a large, long-standing blind area.
• 26:47
  SPEAKER_00: For advanced glaucoma, the limiting problem is likely cell loss.
• 26:52
  SPEAKER_00: ER100 does not appear to be a retinal ganglion cell replacement therapy.
• 26:56
  SPEAKER_00: It supplies reprogramming factors to existing cells.
• 26:59
  SPEAKER_00: It is not designed to create new retinal ganglion cells from stem cells or convert other retinal cells into replacement neurons.
• 27:08
  SPEAKER_00: For acute non-arteritic anterior ischemic optic neuropathy, the situation may be more favorable because treatment occurs within 14 days when some injured cells could still be salvageable.
• 27:20
  SPEAKER_00: Major scientific and medical risks.
• 27:22
  SPEAKER_00: Uncontrolled reprogramming, OSK factors influence broad gene networks.
• 27:28
  SPEAKER_00: The desired effect is partial rejuvenation, but the boundary between rejuvenation and loss of cell identity may be narrow.
• 27:35
  SPEAKER_00: If retinal ganglion cells become too developmentally immature, they could lose specialized electrical properties or alter their connections.
• 27:43
  SPEAKER_00: If only some cells reprogram successfully, the retina could become a mosaic of cells in different functional states.
• 27:50
  SPEAKER_00: Partial reprogramming is therefore not simply an on or off switch.
• 27:54
  SPEAKER_00: It is a dose, timing, cell type, and tissue-dependent process.
• 27:59
  SPEAKER_00: Tumor formation.
• 28:00
  SPEAKER_00: The omission of CMIC is intended to reduce cancer risk, and the eye is a localized treatment site.
• 28:06
  SPEAKER_00: The mouse studies reported no obvious tumors during the tested period.
• 28:10
  SPEAKER_00: However, OCT4, SOX2, and KLF4 are powerful cell state regulators.
• 28:16
  SPEAKER_00: Incomplete reprogramming has been associated with abnormal cell states and tumorogenesis in other experimental contexts.
• 28:22
  SPEAKER_00: A rare tumor may not appear during a short animal study.
• 28:26
  SPEAKER_00: Human cells may respond differently from mouse cells.
• 28:29
  SPEAKER_00: AAV can persist in non-dividing cells, so the vector may remain after doxycycline is stopped.
• 28:35
  SPEAKER_00: Reviews of partial reprogramming continue to identify oncogenic risk as a major unresolved issue.
• 28:42
  SPEAKER_00: Partial reprogramming reviews.
• 28:44
  SPEAKER_00: Loss of retinal ganglion cell identity.
• 28:47
  SPEAKER_00: The entire therapeutic concept depends on preserving identity.
• 28:51
  SPEAKER_00: A retinal ganglion cell cannot simply become younger in a general sense.
• 28:55
  SPEAKER_00: It must remain a retinal ganglion cell.
• 28:58
  SPEAKER_00: The clinical trial therefore needs more than short-term visual testing.
• 29:01
  SPEAKER_00: It needs long-term evidence that treated cells remain stable and that there is no delayed alteration in retinal circuitry.
• 29:08
  SPEAKER_00: Immune reactions to the adenoassociated virus, adenoassociated virus vectors are widely used in gene therapy, but they are not immunologically invisible.
• 29:18
  SPEAKER_00: Potential problems include pre-existing antibodies that reduce transduction, new neutralizing antibodies that make repeat treatment difficult, inflammation inside the eye, uveitis, retinal damage, complement activation, and immune destruction of transduced cells.
• 29:35
  SPEAKER_00: Intravitrial delivery can expose the vector to immune cells in the vitreous and retina.
• 29:40
  SPEAKER_00: The trials antibody testing, cellular immune testing, and viral shedding tests are therefore important safety components.
• 29:48
  SPEAKER_00: Food and drug administration, ocular adenoassociated virus review.
• 29:53
  SPEAKER_00: Off-target expression AAV2 delivered into the vitreous is intended to reach retinal ganglion cells, but delivery is not perfectly cell-specific.
• 30:02
  SPEAKER_00: Expression in other retinal cells, glial cells, or tissues could produce unexpected effects.
• 30:09
  SPEAKER_00: The clinical trials.gov record includes biodistribution testing, but it will not provide a complete map of every cell that receives the vector.
• 30:17
  SPEAKER_00: Human retinal tissue is difficult to sample directly, so some off-target risks may remain difficult to measure.
• 30:24
  SPEAKER_00: Uncertain durability AAV-based expression can be long-lasting, which is useful when a treatment requires a single injection.
• 30:31
  SPEAKER_00: It also creates a safety challenge.
• 30:33
  SPEAKER_00: Once the vector has entered cells, stopping doxycycline may stop active OSK production, but it does not remove the vector.
• 30:41
  SPEAKER_00: The mouse data suggests that visual benefits may persist after OSK is switched off, but the benefit can also gradually decline.
• 30:49
  SPEAKER_00: If repeated activation or repeat injection is needed, preexisting immunity may make retreatment difficult.
• 30:56
  SPEAKER_00: Ongoing glaucoma stress ER100 does not lower intraocular pressure.
• 31:01
  SPEAKER_00: If pressure-related mechanical stress continues, rejuvenated cells may still be damaged.
• 31:07
  SPEAKER_00: This means ER-100, if eventually proven useful, would most likely be added to, not substituted for, pressure-lowering treatment.
• 31:15
  SPEAKER_00: Trial interpretation risks.
• 31:17
  SPEAKER_00: The phase 1 study is small, sequential, and apparently not randomized against a sham procedure.
• 31:22
  SPEAKER_00: Visual field testing has substantial variability.
• 31:26
  SPEAKER_00: Patients can improve simply because they become more familiar with the test.
• 31:30
  SPEAKER_00: An apparent improvement must therefore be distinguished from learning effects, better testing reliability, changes in cataract or refraction, intraocular pressure changes, inflammation-related temporary changes, regression toward the average, or chance findings in a very small sample.
• 31:49
  SPEAKER_00: How strong is the evidence that epigenetic aging causes retinal ganglion cell dysfunction?
• 31:54
  SPEAKER_00: The evidence is suggestive and mechanistically interesting, but not definitive in humans.
• 31:59
  SPEAKER_00: Evidence supporting a causal role, injury can create age-like molecular changes.
• 32:04
  SPEAKER_00: The mouse work reported that optic nerve injury in young animals produced DNA methylation changes resembling those seen during aging.
• 32:13
  SPEAKER_00: OSK reversed some of those patterns while improving retinal function.
• 32:17
  SPEAKER_00: This links injury, aging-like epigenetic change, and functional decline.
• 32:21
  SPEAKER_00: OSK effects require active DNA demethylation.
• 32:25
  SPEAKER_00: The beneficial effect depended on TET-1, TET2, and TDG-related demethylation processes.
• 32:30
  SPEAKER_00: This suggests that the epigenetic changes may be functionally involved rather than merely passive markers.
• 32:36
  SPEAKER_00: Nature study.
• 32:38
  SPEAKER_00: Human glaucoma progression is associated with biological age acceleration.
• 32:43
  SPEAKER_00: A 2024 study of patients with primary open-angle glaucoma reported that greater blood-based epigenetic age acceleration was associated with faster glaucoma progression.
• 32:54
  SPEAKER_00: That supports a relationship between biological aging and disease behavior.
• 32:59
  SPEAKER_00: Important limitations.
• 33:01
  SPEAKER_00: Blood-based epigenetic age is not the same as the epigenetic age of retinal ganglion cells.
• 33:07
  SPEAKER_00: The study was observational, so it cannot establish whether accelerated epigenetic aging causes glaucoma progression or reflects other factors associated with it.
• 33:15
  SPEAKER_00: Glaucoma also involves many biological pathways, including intraocular pressure-related stress, reduced blood supply, mitochondrial dysfunction, oxidative stress, inflammation, excitotoxicity, abnormal axonal transport, and genetic susceptibility.
• 33:32
  SPEAKER_00: Epigenetic changes may be one important contributor rather than the single root cause.
• 33:37
  SPEAKER_00: There is also a conceptual problem with epigenetic clocks.
• 33:41
  SPEAKER_00: A clock can accurately predict age without identifying the specific molecular changes that cause functional decline.
• 33:47
  SPEAKER_00: Reversing a clock does not automatically reverse disease.
• 33:52
  SPEAKER_00: Overall assessment.
• 33:54
  SPEAKER_00: Mouse glaucoma and injury models.
• 33:56
  SPEAKER_00: Reasonably strong evidence that OSK can alter cellular state and improve function.
• 34:01
  SPEAKER_00: Human glaucoma biology.
• 34:03
  SPEAKER_00: Growing evidence that epigenetic aging is associated with disease progression.
• 34:07
  SPEAKER_00: Proof that epigenetic drift is the dominant cause of human retinal ganglion cell dysfunction.
• 34:12
  SPEAKER_00: Not established.
• 34:14
  SPEAKER_00: Proof that resetting methylation will restore lost human visual field.
• 34:18
  SPEAKER_00: Absent.
• 34:19
  SPEAKER_00: A recent independent review of glaucoma neuroprotective strategies described OSK as a conceptually important approach, but noted unresolved questions about how reliably the mechanism translates to primate retinal ganglion cells and the need for independent replication.
• 34:38
  SPEAKER_00: What would count as convincing evidence that glaucoma damage was reversed?
• 34:42
  SPEAKER_00: A convincing claim would require much more than a lower epigenetic age or a favorable safety result.
• 34:48
  SPEAKER_00: Evidence needed in a controlled clinical trial.
• 34:51
  SPEAKER_00: A strong phase 2 or phase 3 study would ideally be randomized, masked where possible, sham controlled, large enough to measure real visual field changes, and conducted on top of standardized intraocular pressure treatment.
• 35:05
  SPEAKER_00: Functional evidence.
• 35:07
  SPEAKER_00: The most important outcome would be a reproducible improvement in visual function, such as improvement in Humphrey visual field mean deviation, recovery at previously damaged visual field locations, improved contrast sensitivity, improved low contrast vision, improvement in patient reported visual function, and possibly improved visual evoked potential responses.
• 35:29
  SPEAKER_00: The improvement would need to exceed normal test-retest variability and persist for at least 6 to 12 months, preferably longer.
• 35:38
  SPEAKER_00: Structural evidence.
• 35:40
  SPEAKER_00: Functional improvement should be accompanied by compatible structural findings, such as stabilization or increase in ganglion cell layer thickness, stabilization or improvement in retinal nerve fiber layer measurements, improved optic nerve architecture, or other validated imaging evidence of preserved or restored retinal ganglion cell structure.
• 36:01
  SPEAKER_00: A thicker retinal layer by itself would not be enough.
• 36:04
  SPEAKER_00: Swelling, segmentation errors, or inflammation could falsely increase thickness measurements.
• 36:10
  SPEAKER_00: Proof that the effect is independent of pressure.
• 36:14
  SPEAKER_00: The trial would need to show that improvement is not simply due to lower intraocular pressure.
• 36:19
  SPEAKER_00: Ideally, intraocular pressure would remain stable, pressure-lowering treatments would be balanced between groups, and the visual benefit would appear in the ER100 group, but not in the SHAM group.
• 36:32
  SPEAKER_00: Evidence of true restoration rather than testing artifacts.
• 36:36
  SPEAKER_00: For a claim of reversal, researchers would need to demonstrate improvement in repeat visual fields, improvement in different types of visual testing, consistent improvement across multiple centers, dose response behavior, persistence after doxycycline is stopped, and no explanation based on cataract surgery, refractive correction, pressure reduction, or learning effects.
• 36:59
  SPEAKER_00: Evidence of neural repair.
• 37:01
  SPEAKER_00: The strongest evidence would combine improved visual field, improved retinal ganglion cell structure, improved retinal ganglion cell electrical function, stable or regenerated axon architecture, and durable patient-reported benefit.
• 37:15
  SPEAKER_00: Directly proving that new axons have reconnected correctly to the human visual cortex may not be practical with current imaging, but the clinical pattern would need to be consistent with genuine neural repair rather than a laboratory biomarker change.
• 37:30
  SPEAKER_00: Likely development timeline if phase one is safe.
• 37:33
  SPEAKER_00: The current trial's estimated primary completion is May 2027, with long-term follow-up extending to March 2032.
• 37:43
  SPEAKER_00: If the trial shows no major safety problem, a plausible, not guaranteed development sequence would be.
• 38:11
  SPEAKER_00: Later than that, broader use, if approved, because gene therapies require extensive long-term safety monitoring.
• 38:18
  SPEAKER_00: Development could move faster for acute non-arteritic anterior ischemic optic neuropathy if the visual recovery signal is large and consistent, because the injury is recent and the treatment population is easier to define.
• 38:31
  SPEAKER_00: Chronic glaucoma would likely require longer trials because progression and visual field change occur over years.
• 38:39
  SPEAKER_00: This timeline is an evidence-based estimate, not a company forecast.
• 38:44
  SPEAKER_00: Many phase one gene therapy programs do not progress because of dose limitations, immune reactions, inadequate efficacy, manufacturing problems, or long-term safety concerns.
• 38:55
  SPEAKER_00: Final verdict?
• 38:56
  SPEAKER_00: Restoration era or first credible experiment?
• 38:59
  SPEAKER_00: ER-100 is more than a speculative supplement or a laboratory-only longevity concept.
• 39:04
  SPEAKER_00: It is a real, regulated, first in-human gene therapy trial based on peer-reviewed mouse research and publicly reported primate experiments.
• 39:13
  SPEAKER_00: The preclinical evidence includes more than improved biomarkers, retinal ganglion cell survival after optic nerve injury, axon regeneration in a mouse injury model, improved visual behavior in mouse glaucoma, improved retinal electrical function, long-lasting benefit in a mouse follow-up study, and company-reported pattern electroretinogram recovery and axon preservation in non-human primates with experimental ischemic optic neuropathy.
• 39:41
  SPEAKER_00: That makes ER-100 scientifically credible enough to deserve careful clinical testing.
• 39:47
  SPEAKER_00: But the leap from these findings to human glaucoma reversal remains substantial.
• 39:52
  SPEAKER_00: The therapy has not yet shown that it can replace dead retinal ganglion cells, rebuild a chronically damaged human optic nerve, restore an established visual field, produce durable human visual improvement, or remain safe after years of altered gene expression.
• 40:08
  SPEAKER_00: The most realistic early success would be neuroprotection and functional rescue of surviving retinal ganglion cells.
• 40:15
  SPEAKER_00: A modest recovery of visual sensitivity would be plausible if enough cells remain alive.
• 40:21
  SPEAKER_00: Large-scale restoration of long-standing visual field loss would require evidence that ER100 can achieve genuine axonal regeneration and correct reconnection, something no current human data demonstrate.
• 40:34
  SPEAKER_00: The central answer is therefore clear.
• 40:36
  SPEAKER_00: Glaucoma has not finally entered the era of proven optic nerve restoration.
• 40:42
  SPEAKER_00: But the first credible human experiment aimed at making that possible has begun.
• 40:47
  SPEAKER_00: All links to sources are available in the text version of this article.
• 40:51
  SPEAKER_00: You can find the full article at VisualFieldtest.com.
• 40:55
  SPEAKER_00: Thanks for listening.
• 40:57
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.